Meghan R. Flanagan, MD, MPH, noted the nuanced discussions that multidisciplinary tumor boards should have to optimize breast cancer management strategies.
Back
Dr Flanagan on the Importance of Multidisciplinary Breast Cancer Tumor Boards
Dr Flanagan on the Importance of Multidisciplinary Breast Cancer Tumor Boards
Episodes
All
All
Meghan R. Flanagan, MD, MPH, notes takeaways from a multidisciplinary tumor board discussion on how genomic assays can guide treatment decisions for DCIS.
Meghan R. Flanagan, MD, MPH, discusses the multidisciplinary complexities that arise when trying to coordinate de-escalated breast cancer care.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
5